Clinicians and pharmacists who prescribe and fill medications containing the drug are advised to inform patients to avoid exposure to pets.
The Food and Drug Administration (FDA) has approved Ameluz (aminolevulinic acid HCl; Biofrontera) gel, in combination with photodynamic therapy using BF-RhodoLED lamp, for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp.
A considerable proportion of patients with actinic keratosis (AK) receiving long-term topical treatment have poor persistence or adherence, according to a study published online in the British Journal of Dermatology.
Pulse photodynamic therapy (pulse-PDT) and corticosteroid pulse-PDT reduce treatment-induced erythema in patients treated for actinic keratoses (AK), according to a study published online Feb. 8 in the British Journal of Dermatology.
The Food and Drug Administration (FDA) is warning about reports of severe allergic reactions and herpes zoster associated with the use of Picato (ingenol mebutate topical gel).
Two cases of squamous cell carcinoma (SCC) have been described, with rapid onset after application of ingenol mebutate gel for treatment of actinic keratosis (AK).
For actinic keratoses (AKs), photodynamic therapy (PDT) is associated with improved response compared with cryotherapy.
For patients with facial photodamage and actinic keratoses (AK), treatment with a new fractional resurfacing technique that uses a 1927-nm nonablative thulium laser reduces the number of facial AK and produces noticeable improvement in overall photodamage.